South San Francisco, CA, United States of America

Matthew Epplin

USPTO Granted Patents = 5 

Average Co-Inventor Count = 19.7

ph-index = 2

Forward Citations = 5(Granted Patents)


Location History:

  • South San Francisco, CA (US) (2022 - 2023)
  • San Francisco, CA (US) (2024)

Company Filing History:


Years Active: 2022-2024

Loading Chart...
5 patents (USPTO):

Title: The Innovative Contributions of Matthew Epplin

Introduction

Matthew Epplin is a notable inventor based in South San Francisco, CA. He has made significant contributions to the field of chemistry, particularly in the development of compounds with therapeutic applications. With a total of five patents to his name, Epplin's work is recognized for its potential impact on medical treatments.

Latest Patents

Among his latest patents is a process for preparing tetralin compounds. This patent describes processes and intermediates useful for preparing specific compounds at multigram or kilogram scale. Another significant patent involves tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2α. This patent outlines compounds that inhibit HIF-2α and discusses their use in treating various diseases, including cancer and immune-related disorders.

Career Highlights

Matthew Epplin is currently employed at Arcus Biosciences, Inc., where he continues to innovate and contribute to the field of biochemistry. His work focuses on developing compounds that can lead to advancements in medical treatments.

Collaborations

Epplin collaborates with talented individuals such as Joel Worley Beatty and Samuel Lawrie Drew. These partnerships enhance the research and development efforts at Arcus Biosciences, Inc.

Conclusion

Matthew Epplin's innovative work and patents reflect his commitment to advancing medical science. His contributions have the potential to lead to significant breakthroughs in the treatment of various diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…